Zestagen ^None

Zestagen is a Swiss biotech company that develops light chain mAbs targeting Extracellular Heat Shock Protein-90 (ehsp90), which is involved in cancer cell motility, migration, and metastasis. Zestagen's mAbs bind to ehsp90 on cancer cells' surfaces, inhibiting metastasis in preclinical cancer animal models. Unlike small molecule hsp90 inhibitors, Zestagen's mAbs are predicted to have a better therapeutic index in cancer patients.